Phototherapy achieves significant cost savings by the delay of drug based treatment in psoriasis by Foerster, John & Dawe, Robert
                                                                    
University of Dundee
Phototherapy achieves significant cost savings by the delay of drug based treatment
in psoriasis
Foerster, John; Dawe, Robert
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Foerster, J., & Dawe, R. (2019). Phototherapy achieves significant cost savings by the delay of drug based
treatment in psoriasis. Photodermatology, Photoimmunology & Photomedicine.
https://doi.org/10.1111/phpp.12511
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. Dec. 2019
Photodermatol Photoimmunol Photomed. 2019;00:1–7.	 	 	 | 	1wileyonlinelibrary.com/journal/phpp
 
Received:	10	July	2019  |  Revised:	21	August	2019  |  Accepted:	1	September	2019
DOI: 10.1111/phpp.12511  
O R I G I N A L  A R T I C L E
Phototherapy achieves significant cost savings by the delay of 
drug‐based treatment in psoriasis
John Foerster1  |   Robert Dawe1,2
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
































Conclusions: Healthcare	 providers	may	 achieve	 significant	 cost	 savings	 by	 imple-
menting	and/or	widening	access	to	phototherapy.
K E Y W O R D S
health	economics,	NB‐UVB,	psoriasis,	treatment	pathways
1  | INTRODUC TION
Narrowband	 UVB	 (NB‐UVB)	 treatment	 is	 effective	 in	 psoriasis	
as	 shown	 in	numerous	clinical	 trials,1-5	 as	well	 as	 in	a	 recent	de-
tailed	real‐world	study	which	also	showed	that	NB‐UVB	achieved	
significant	reduction	in	the	use	of	steroid	creams.6	Although	widely	
used,	 the	 treatment	 is	 not	 uniformally	 available	 and,	 indeed,	 ac-
cess	appears	to	be	decreasing	in	the	United	States.7 The main lim-
itations	of	the	treatment	include	inconvenience	for	patients,	as	the	
treatment	requires	three	times	weekly	attendance,	a	perception	of	







commercial	 sponsors,	 there	 is	 a	 relative	dearth	on	both	efficacy	as	
well	as	economics	data	for	phototherapy.	In	turn,	this	leads	to	under‐
representation	or	even	exclusion	 from	comparative	 treatment	anal-








support	staff),	as	well	as	an	exhaustive	 list	of	 indirect	cost	 (pension	




the	 savings	 generated	 for	 the	healthcare	provider	 through	photo-
therapy	by	 the	 concomitant	delay	 and/or	 avoidance	of	 alternative	
















All	data	generated	 in	 this	study	were	obtained	 in	accordance	with	
the	 Declaration	 of	 Helsinki	 and	 in	 compliance	 with	 local	 govern-
ance	approval	regulations	(Caldicot	number	CSAppJF2101;	the	use	





















2.3 | Cost factors in third‐line treatment
Laboratory	monitoring	cost	 incurred	by	 the	provider	was	supplied	
by	NHS	Tayside	Blood	Sciences	and	 is	detailed	 in	their	application	
to	various	drugs	 in	Figure	S1.	The	 frequency	of	 laboratory	 review	
was	set	at	four	times	annually	(low	and	medium)	or	six	times	annu-









A	number	of	 cost	 emerging	with	drug	 treatment	were	not	mod-
elled	due	to	difficulty	in	establishing	precise	actual	frequencies	of	
episodes.	These	include	(a)	treatment	failures	occuring	at	less	than	











Costs	 for	 methotrexate,	 acitretin,	 ciclosporine	 were	 accessed	
through	 NHS	 drug	 tariff	 (http://www.drugt	ariff.nhsbsa.nhs.uk),	
respectively.	 Cost	 for	 dimethyl	 fumarate	was	 accessed	 at	 https	://
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cost	of	£9000	and	£11	000,	 respectively,	was	set	 for	 the	medium	
cost	 scenario	 (see	Results)	 but	 can	be	 altered	 to	 reflect	 local	 cost	
figures.
3  | RESULTS
3.1 | The post‐phototherapy psoriasis treatment 
pathway
In	order	 to	delineate	the	cost	 for	 treatment	of	psoriasis	 that	 the	
provider	would	have	incurred	in	the	absence	of	phototherapy,	we	
used	 the	 treatment	pathway	currently	operative	 in	NHS	Tayside	
(Figure	1,	see	below	for	the	details)	which	is	similar	to	that	applied	








study,	use	of	apremilast,	 licensed	in	2015,	 is	 low	and	has	further	
decreased	 in	 NHS	 Tayside	 (Financial	 year	 2016/17:66	 prescrip-





The	 basic	 assumption	 is	 simply	 that	 completion	 of	 a	 course	 of	
NB‐UVB	 and	 PUVA,	 respectively,	 will	 delay	 the	 use	 of	 alterna-













“Review”	 refers	 to	 a	 clinician	 review	 appointment	 which	 is	




elements	 methotrexate,	 cyclosporine,	 dimethyl	 fumarate,	 1st	 line	
biologic,	2nd	 line	biologic,	respectively.	P	 incorporates	the	3%	dis-
count	rate	commonly	applied	in	cost‐effectiveness	modelling,16 re-





Any	 cost	 savings	 for	 each	 treatment	 step	 will	 not	 be	 realized	
instantaneously,	but	at	various	subsequent	time	points,	wherefore	
Equation	1	 represents	 cumulative	 savings	 (effects	of	 inflation	 and	
varying	interest	rates	are	ignored).	The	cost	for	each	treatment	step	
was	set	for	a	12‐month	treatment	window,	which	is	also	conserva-
tive,	 since	most	 treatments	 are	 dispensed	 for	 longer	 (eg	we	 have	
previously	reported	median	treatment	duration	of	methotrexate	as	
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cost	savings	incurred	by	delay	of	the	subsequent	treatment	step	by	
one	financial	year.







courses	 of	 phototherapy	 (either	UVB	 or	 PUVA).	 Therefore,	 the	
actual	 cost	 incurred	 for	 the	 provider	 NHS	 Tayside	 has	 in	 fact	
been	 788/656	 =	 1.20	 times	 the	 cost	 of	 one	 treatment	 course,	
which	 has	 accordingly	 incorporated	 as	 correction	 factor	 into	
Equation	1.






including	 phototherapy,	 and	 we	 therefore	 have	 refrained	 from	 in-
corporating	assumptions.	However,	 it	 is	worth	noting	that	we	have	
previously	 shown	 that	 the	 degree	 of	 disease	 control	 by	 NB‐UVB	
is	 comparable	 to	 that	 achieved	 by	 methotrexate	 under	 real‐world	
conditions,6,17,18	and	that	response	rates	are	similar	to	clinical	study	
results	reported	for	apremilast,	DMF	and	etanercept.19-21	Although	
the	 subjectively	 experienced	 degree	 of	 disease	 control,	 that	 is	 the	




3.6 | Modelling of NB‐UVB‐only cost differences
Since	many	 providers	may	 only	 offer	NB‐UVB	 treatment,	 it	 is	 in-
structive	to	calculate	hypothetical	cost	differences	associated	only	
with	NB‐UVB.	 In	 this	 alternative	 scenario,	 the	delay	 in	 the	use	of	
third‐line	treatment	is	shortened	from	24	to	12	months	and	no	CR	
review	is	required	prior	to	PUVA,	yielding	Equation	2:
3.7 | Modelling the likelihood of 
alternative treatments
For	 the	 calculation	of	 cost	 savings	by	NHS	Tayside,	 the	most	 fre-
quently	used	dose	ranges	are	summarized	in	Table	2.	The	likelihood	
for	alternative	treatments	(Table	1)	was	set	based	on	the	economical	





















Likelihood of use (%)b
Cost displaced per patient by 
UVB (£)c
Low Medium Highd Low Medium High
Methotrexate 50 66 70 349 461 492
Acitretin 30 40 44 221 303 337
Ciclosporine 5 10 15 38 77 141
Fumarate 18 22 25 831 916 1,138
1st	biologic 3 5 7 292 487 682












TA B L E  1  Drug‐associated	costs	
displaced	by	phototherapya
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that	the	provider	would	have	incurred	significant	additional	cost	in	
the	 absence	 of	 either	 combined	 phototherapy	 (NB‐UVB	 +	 PUVA)	
or	NB‐UVB	only.	The	numbers	in	the	“medium”	scenario	reflect	ac-
tual	savings	most	closely	based	on	local	treatment	patterns	(includ-























for	 these	 high‐cost	 drugs.	 By	 contrast,	we	 here	 exploit	 detailed	
knowledge	 of	 the	 response	 of	 psoriasis	 to	 phototherapy	 as	well	
as	comparator	 treatments6,17‐21	 in	order	 to	simplify	modelling	by	
aligning	 it	with	clinical	practice:	regardless	of	a	specific	PASI	 im-
provement,	 a	 given	 patient	 is	 likely	 to	 progress	 along	 the	 treat-
ment	pathway	if	a	subjectively	“insufficient”	experienced	level	of	







Excel	 files	1,	 2)	 obviating	 any	 further	 need	 to	 adjust	 for	 greater	
health	benefit.	Importantly,	discounting	means	that	even	changing	
TA B L E  2  Drug	doses	and	fixed	drug	prices	used	to	calculate	
cost	savings	associated	with	displacement	of	drug	treatment	by	
phototherapy	(UVB/PUVA)a
Treatment scenariob,g Lowb,c Medium High
Methotrexate 12.5	mg 15	mg 20	mg
Acitretin 10	mg 25	mg 30	mg
Ciclosporine 200	mgf 200	mg 300	mg
Dimethyl	fumarate 4	tabsd 4.5	tabs 5	tabs
1st	line	biologic £7000e £9000 £9000





















Cost (£) Low High
Per	Patient NB‐UVB	+	PUVA 3727 2469 5284
For	all	patientsb Mio	2.44 Mio	1.62 Mio	3.47
Per	Patient NB‐UVB	onlyc 2169 1849 2948
For	all	patients Mio	1.42 Mio 1.21 Mio	1.93
Per	Patient NB‐UVB	discountedd 1685 1479 2397








TA B L E  3  Cost	savings	associated	with	
delay/avoidance	of	third‐line	treatment	by	
NHS	Tayside.a
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the	drug	cost	 from	£9000	 to	£3000,	 as	 currently	 the	case	after	
biosimilar	introduction,	only	has	a	minor	impact	on	the	overall	cost	
savings.	Since	the	model	shown	in	Figure	1	in	fact	represents	the	




Our	 study	has	 two	main	 limitations.	First,	we	do	not	 consider	pa-
tient‐incurred	cost,	in	particular	absence	from	work	place	enforced	
by	treatment	attendance.	In	this	regard,	it	should	be	noted	that	many	









In	 terms	of	 the	dominant	cost	 factor,	 staff	 time,	we	previously	
detailed	direct	and	indirect	staff	hours	required	to	supply	NB‐UVB,	
facilitating	more	 predictive	model	 building.6	 The	 key	 factor,	 iden-
tified	 therein,	 driving	 cost‐effectiveness	was	 low	 actual	 hands‐on	
time,	 requiring	 only	 0.45	±	 0.14	 staff	 hours	 (including	 both	 direct	
and	support	staff	roles)	per	completed	NB‐UVB	course.	The	obvious	






propriate	as	 long‐term	 intercurrent	 treatment	and	can	be	adminis-
tered	 in	clinical	 settings	often	 limiting	 for	drug	 treatment,	 such	as	
late	pregnancy,	anticipated	family	planning,	or	hepatic	dysfunction.	
Although	we	have	 shown	 that	even	 for	 treatment	 sites	with	 small	
patient	 throughput	 (around	100	courses	per	year)	 cumulative	cost	
are	similar	to	larger	sites,6	the	cost	savings	potential	is	of	particular	
relevance	to	large	providers.
4.3 | NB‐UVB and phototherapy in psoriasis 
treatment pathways
The	 cost	 savings	 potential	 in	 conjunction	 with	 established	 effi-
cacy	begs	the	question	as	to	why	this	treatment	is	not	more	widely	

















sented	 here	will	 encourage	 providers	 to	 re‐evaluate	 phototherapy,	
and	in	particular	NB‐UVB,	within	psoriasis	treatment	pathways.
Finally,	phototherapy	is	also	used	for	many	other	diseases,	with	
good	 controlled	 study	 evidence	 supporting	 efficacy	 in	 eczema	
and	 chronic	 urticaria,31‐33	 offering	 further	 potential	 econonomical	
synergy.
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